arrow
S

Sahar Barjesteh van Waalwijk van Doorn-Khosrovani

cz health insurance
H指数:17
被引数:2,934

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Overcoming the barriers to treatment of rare cancer patients in the era of precision oncology: A call to action

克服精准肿瘤学时代罕见癌症患者的治疗障碍:一项行动倡议

2025-08-140
OAAI
Addressing uncertainties of clinical value and improving access for newly authorised indications through DRUG-Access Protocol (DAP)-like platforms: Joint collection and evaluation of real-world evidence

通过类似DRUG-Access Protocol (DAP)的平台解决临床价值的不确定性并改善新授权适应症的准入:真实世界证据的联合收集与评估

2024-09-010
PRE
Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol

Cemiplimab在局部晚期或转移性皮肤鳞状细胞癌中的应用: 来自药物访问方案的前瞻性真实数据

2024-04-014
OA
Outcome-based reimbursement in Central-Eastern Europe and Middle-East
2022-09-238
OAAI
Harmonising patient-access programmes
2020-09-010
OAAI
Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients
2019-05-0127
OAAI
Long-term Follow-up Assessing Renal Angiomyolipoma Treatment Patterns, Morbidity, and Mortality: An Observational Study in Tuberous Sclerosis Complex Patients in the Netherlands

评估肾血管平滑肌脂肪瘤治疗模式、发病率和死亡率的长期随访: 荷兰结节性硬化症患者的一项观察性研究

2015-10-0196
OAAI